Comparative

OMIA group 1512

Transitional cell carcinoma

The chain reaches the human disease urinary bladder cancer, which Mondo defines as: “A primary or metastatic malignant neoplasm involving the bladder.”

The chain

From the animal disease to the drugs. The page shows what each step found and where the chain stopped. It does not say whether the animal is a model of a human disease.

  1. Animal disease

    Reached

    OMIA records it in 2 species entries marked as a defect.

  2. Human disease

    Reached

    1 Mondo disease.

  3. Human gene

    Reached

    3 human genes.

  4. Target evidence

    Reached

    3 Open Targets associations, with a best score of 0.29.

  5. Drugs

    Reached

    34 ChEMBL drugs, 11 approved. At least one has been tested for this disease.

Natural-model score

How complete and how well supported the chain to each human disease is, out of 100, by stated rules. It does not say that the animal is a validated model of the human disease. How the score works.

urinary bladder cancer

62.0 out of 100

Part Computed from Points
Target evidence Open Targets score of 0.29 10.0 of 35
Drugs A drug has reached phase 3 for this disease 20.0 of 25
Ortholog One to one ortholog 20.0 of 20
Both routes One route found this disease 5.0 of 10
Species 2 naturally occurring species entries marked as a defect 7.0 of 10

Species

The chain follows only the species entries that OMIA marks as a defect.

Species Scientific name OMIA entry A defect
dog Canis lupus familiaris OMIA:001512-9615 Yes
fishing cat Prionailurus viverrinus OMIA:001512-61388 Yes

Genes

Each gene OMIA records for a species entry, and the human gene it reaches through Ensembl's orthologs.

Species Animal gene Human gene Ortholog
dog BRAF B-Raf proto-oncogene, serine/threonine kinase NCBI Gene 475526 BRAF Ensembl one to one
dog MAP2K1 mitogen-activated protein kinase kinase 1 NCBI Gene 478347 MAP2K1 Ensembl one to one
dog NIPAL1 NIPA like domain containing 1 NCBI Gene 482138 NIPAL1 Ensembl one to one
fishing cat No gene OMIA records no gene for this species entry.

Human diseases

Two routes lead from an OMIA group to a Mondo human disease: OMIA's own Mondo link, and the group's OMIM numbers through Mondo's cross-references.

Mondo disease Name Found by
MONDO:0001187 urinary bladder cancer A primary or metastatic malignant neoplasm involving the bladder. OMIA's OMIM numbers

Target evidence

Each Open Targets association between one of the group's human genes and one of its human diseases, with its overall score and the score for each kind of evidence.

Human gene Human disease Score Evidence Kinds of evidence
BRAF urinary bladder cancer 0.29 32 Somatic mutation 0.43 Literature 0.19 Known drug 0.14
MAP2K1 urinary bladder cancer 0.07 15 Literature 0.50 Known drug 0.06
NIPAL1 urinary bladder cancer 0.00 1 Literature 0.01

Drugs

A drug acts on BRAF and MAP2K1 and has been tested for this disease.

Drug Acts on How Latest stage Tested for this disease
Sorafenib BRAF inhibitor Approved Phase 2 for urinary bladder cancer
Selumetinib MAP2K1 inhibitor Approved Phase 1 for urinary bladder cancer
Binimetinib MAP2K1 inhibitor Approved No
Cobimetinib MAP2K1 inhibitor Approved No
Dabrafenib BRAF inhibitor Approved No
Encorafenib BRAF inhibitor Approved No
Mirdametinib MAP2K1 inhibitor Approved No
Regorafenib BRAF inhibitor Approved No
Tovorafenib BRAF inhibitor Approved No
Trametinib MAP2K1 inhibitor Approved No
Vemurafenib BRAF inhibitor Approved No
Avutometinib MAP2K1 inhibitor Phase 3 No
Naporafenib BRAF inhibitor Phase 3 No
Refametinib MAP2K1 inhibitor Phase 3 No
Belvarafenib BRAF inhibitor Phase 2 No
Ci-1040 MAP2K1 inhibitor Phase 2 No
E-6201 MAP2K1 inhibitor Phase 2 No
Pimasertib MAP2K1 inhibitor Phase 2 No
Plixorafenib BRAF inhibitor Phase 2 No
Raf-265 BRAF inhibitor Phase 2 No
Tak-733 MAP2K1 inhibitor Phase 2 No
Cep-32496 BRAF inhibitor Phase 1/2 No
Lifirafenib BRAF inhibitor Phase 1/2 No
Wx-554 MAP2K1 inhibitor Phase 1/2 No
Xl-281 BRAF inhibitor Phase 1/2 No
As-703988 MAP2K1 inhibitor Phase 1 No
Azd-8330 MAP2K1 inhibitor Phase 1 No
Ly-3009120 BRAF inhibitor Phase 1 No
Rg-7167 MAP2K1 inhibitor Phase 1 No
Rg-7256 BRAF inhibitor Phase 1 No
Ro-4987655 MAP2K1 inhibitor Phase 1 No
Arq-736 Free Acid BRAF inhibitor Unknown No
Balamapimod MAP2K1 inhibitor Unknown No
Lgx-806 BRAF inhibitor Unknown No

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.